Home Care Medication Management Program for the Frail Elderly
The purpose of this study is to determine whether a home care medication management program which includes nurse coordination and use of the MD.2 medication-dispensing machine will affect older adults' health outcomes, satisfaction, use of health care services, and health care costs over a one year period. The investigators propose a longitudinal three group repeated measures design, enrolling, and randomly assigning, clients who are discharged from a home health care agency with documented problems in medication management. One group will receive the MD.2 medication dispensing device and nurse coordination, the second group will receive a Medplanner: a simple box that has separate compartments for individual medication times over the course of a week plus nurse coordination, and the final group will receive Usual Care.
The study hypotheses are the following:
H1: With respect to health status outcomes, the MD.2 group will exhibit a more positive trajectory in physical and mental health status, functional status, cognitive status and depressive symptoms over the course of a year than will the Medplanner Group.
H2: With respect to health status outcomes, the Medplanner Group will exhibit a more positive trajectory in physical and mental health status, functional status, cognitive status and depressive symptoms over the course of a year than will the Usual Care Group.
H3: The rate of hospitalization, hospital days and emergency department visits will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H4: The rate of hospitalization, hospital days and emergency department visits will be significantly lower for the Medplanner Group as compared to the Usual Care Group.
H5: The nursing home admission rate will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H6: The nursing home admission rate will be significantly lower for the Medplanner Group as compared to the Usual Care Group.
H7: The total cost of care will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H8: The total cost of care will be significantly lower for the Medplanner Group as compared to The Usual Care Group.
H9: There will be incremental savings in terms of costs per quality adjusted life year (QALY) gained in the MD.2 group compared with the Medplanner Group.
H10: There will be incremental savings in terms of costs per QALY gained in the Medplanner group compared with the Usual Care Group.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53201
- University of Wisconsin-Milwaukee
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 60 and older
- Medicare Primary Payer
- Impaired Medication Management ability as indicated by a score of 1 or higher on OASIS discharge assessment item M0780
- Impaired Cognitive Functioning but able to follow directions with prompting as indicated by a score of 1 or 2 on OASIS discharge assessment item M0560
- working telephone line
- Discharge from home health care
Exclusion Criteria:
- Not English speaking
- Terminal diagnosis or hospice care
- Use of other device for medications
- Medicare via managed care
- Use of private home care agency for medication management
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Machine and NCC
Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
|
MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition.
Additional visits made as needed.
Care is coordinated with other providers such as the primary care physician and pharmacist.
|
|
Experimental: Medplanner and NCC
Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
|
Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition.
Additional visits made as needed.
Care is coordinated with other providers such as the primary care physician and pharmacist.
|
|
Sin intervención: Usual Care Group
Admitted post home health care with no intervention.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Geriatric Depression Scale
Periodo de tiempo: 12 months
|
The Geriatric Depression Scale (GDS) was developed to identify depression in older adults.
The original GDS was 30 questions, however, fifteen- and five-question versions also exist.
When tested on the oldest old in the community, the 15-item scale was demonstrated to have favorable reliability and validity results.
Impaired cognitive function (MMSE < 28) reduced the tool's specificity, but sensitivity was not affected by lower MMSE scores.
The tool is scored into depression categories of "none/mild", "moderate" and "major".
|
12 months
|
|
Physical Performance Test (PPT)
Periodo de tiempo: 12 months
|
This functional status test has demonstrated reliability and validity, is easy to administer, can be performed in a reasonable period of time, and imposes little burden on the individual being tested.
Even men and women with mild to moderate dementia are capable of understanding the test and performing activities reliably.
There are 7 items on the test that range in difficulty from very easy to perform (writing a sentence) to challenging (picking up a penny), thus encompassing a spectrum of physical capabilities.
|
12 months
|
|
SF-36 Health Survey
Periodo de tiempo: 12 months
|
This tool is a widely used generic health status questionnaire measuring eight dimensions of health status: physical functioning, role limitations due to physical health problems, bodily pain, social functioning, general mental health, role limitations due to emotional problems, vitality, and general health perceptions.
In addition, the SF-36 can be transformed into a Health State Utility Index that allows for health improvements to be stated in terms of quality adjusted life years (QALYs) gained.
|
12 months
|
|
Mental Mental Status Exam (MMSE)
Periodo de tiempo: 12 months
|
This 11-item measure screens for cognitive abilities in the domains of orientation, memory, attention, recall, language and visual/spatial orientation.
The MMSE may be a categorical or continuous-level variable.
When used as a categorical variable, the MMSE is broken down into 4 levels: (a) score range 24-30 is considered within normal limits (WNL), (b) score range of 18-23 is considered mild cognitive impairment, (c) score range of 12-17 is considered moderate cognitive impairment, and (d) a score range of 11 or less is considered to be severe cognitive impairment.
|
12 months
|
|
Hospitalization
Periodo de tiempo: 12 month enrollment period
|
Medicare claims data will be the source of information for this measure.
|
12 month enrollment period
|
|
Hospital Days
Periodo de tiempo: 12 Month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 Month Enrollment Period
|
|
Emergency Department Visits
Periodo de tiempo: 12 month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 month Enrollment Period
|
|
Medicare Costs
Periodo de tiempo: 12 Month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 Month Enrollment Period
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Karen S Marek, PhD, Arizona State University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 144PG09
- 5R01NR008911 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .